Roble Belko & Company’s Nuvation Bio NUVB Stock Holding History

Roble Belko & Company’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	10	–	–	﹤0.01%	475
2026 Q1	$0	Hold	10	–	–	﹤0.01%	489
2025 Q4	$0	Buy	+10	New	+$62	﹤0.01%	500

Other funds holding NUVB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

LCM

Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Roble Belko & Company's NUVB Position: Q2 2026 in Review

Roble Belko & Company held its Nuvation Bio (NUVB) position steady in Q2 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #475.

Roble Belko & Company first reported a position in NUVB in Q4 2025 and has held it in 3 quarters since. 84 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Roble Belko & Company held 10 shares of Nuvation Bio worth $0 as of Q2 2026.
Roble Belko & Company left its Nuvation Bio share count unchanged in Q2 2026.
Nuvation Bio made up ﹤0.01% of Roble Belko & Company's portfolio in Q2 2026, its #475 holding.
Roble Belko & Company first reported a position in Nuvation Bio in Q4 2025 and has held it in 3 quarters since.
84 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Roble Belko & Company's 13F filing for Q2 2026, filed 24 Jul 2026.